Bactiguard Holding ABCHIX:BACTBS 54 PS Ratio is 22.61 as of Jul. 02, 2026, which is 130% above its 10-year median of 9.81. GuruFocus rates CHIX:BACTBS with a GF Score™ of 54/100 and a GF Value™ of kr274.02. The stock has 2 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Bactiguard Holding AB ranks better than 52.42% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Bactiguard Holding AB's share price is kr128.60.
Bactiguard Holding AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr5.69. Hence, Bactiguard Holding AB's PS Ratio for today is 22.61.
The historical rank and industry rank for Bactiguard Holding AB's PS Ratio or its related term are showing as below:
CHIX:BACTBs'
s PS Ratio Range Over the Past 10 Years
Min: 2.43 Med: 9.81 Max: 33.32
Current: 2.8
During the past 13 years, Bactiguard Holding AB's highest PS Ratio was 33.32. The lowest was 2.43. And the median was 9.81.
CHIX:BACTBs's PS Ratio is ranked better than 52.42% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.93
vs CHIX:BACTBs: 2.80
Bactiguard Holding AB revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Bactiguard Holding AB was -19.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -1.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 5.90% per year.
During the past 13 years, Bactiguard Holding AB's highest 3-Year average Revenue per Share Growth Rate was 15.90% per year. The lowest was -93.40% per year. And the median was 3.40% per year.
Back to Basics: PS Ratio
Bactiguard Holding AB (CHIX:BACTBs) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bactiguard Holding AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bactiguard Holding AB PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Bactiguard Holding AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Bactiguard Holding AB's Share Price of today is kr128.60. Bactiguard Holding AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr5.69.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Bactiguard Holding AB (CHIX:BACTBS) has a PS Ratio of 22.61 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Bactiguard Holding AB and its competitors. This is 130% above median its historical median of 9.81. Over the past decade, Bactiguard Holding AB's PS Ratio has ranged from 2.43 to 33.32. According to the industry distribution chart, Bactiguard Holding AB ranks #383 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 47.6%.
Is Bactiguard Holding AB's PS Ratio too high?
Bactiguard Holding AB's current PS Ratio of 22.61 is 130% above median its 10-year median of 9.81. Over the past 10 years, this metric has ranged from a low of 2.43 to a high of 33.32. The Medical Devices & Instruments industry median PS Ratio is 2.93. Bactiguard Holding AB's value of 22.61 is 671.7% above this industry median. Based on the distribution chart, Bactiguard Holding AB ranks #383 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bactiguard Holding AB has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bactiguard Holding AB ranks #383 out of 805 companies for PS Ratio. This puts Bactiguard Holding AB in the upper half of its industry. The industry median PS Ratio is 2.93. Bactiguard Holding AB's value of 22.61 is 671.7% above this benchmark. Historically, Bactiguard Holding AB's own PS Ratio has ranged from 2.43 to 33.32 over the past decade. While the company's 10-year median is 9.81 vs. the industry median of 2.93, Bactiguard Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.93, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bactiguard Holding AB's current PS Ratio of 22.61 is 671.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Bactiguard Holding AB and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bactiguard Holding AB's current PS Ratio is 22.61, which is 130% above median its own 10-year median of 9.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (CHIX:BACTBS) has a current PS Ratio of 22.61. The stock's GF Value™ is kr274.02, compared to a current price of kr128.60 — trading 53.1% below its estimated fair value. The current PS Ratio is 22.61, which is 130% above median its 10-year median of 9.81 and 671.7% above the Medical Devices & Instruments industry median of 2.93. Bactiguard Holding AB's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Bactiguard Holding AB (CHIX:BACTBS), the current PS Ratio is 22.61 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued.
The current stock price of kr128.60 is trading 53.1% below its estimated GF Value™ of kr274.02.
Key valuation signals for CHIX:BACTBS:
PS Ratio: 22.61 (130% above median its 10-year median of 9.81)
GF Value™: kr274.02 vs. price of kr128.60 (53.1% below fair value)
Industry Position: 671.7% above the Medical Devices & Instruments median (#383 of 805)
No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
54GF Score
Get the complete analysis for CHIX:BACTBS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BACTBS has been successfully added to your 
